Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition

Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition

Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular disease and Parkinson’s disease. Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity. The post Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition appeared first on MedCity News.

Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition – RamaOnHealthcare

Ventyx Biosciences’ lead program, an oral small molecule inhibitor of NLRP3, has encouraging clinical data from separate mid-stage tests in cardiovascular

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

New York, Jan 8, 2026, 08:36 EST — Premarket Eli Lilly shares were up 4.1% at $1,108.09 in premarket trade on Thursday after the drugmaker agreed to buy autoimmune-focused biotech Ventyx Biosciences for $1.2 billion in cash. The deal adds oral drugs for inflammatory diseases and a mid-stage program tied to a cardiovascular condition linked to obesity. “We like that Lilly is taking chances on potentially transformative opportunities,” Cantor Fitz…

Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn - Pharmaceutical Technology

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.